Format

Send to

Choose Destination
Cancer Treat Rev. 2015 Feb;41(2):160-9. doi: 10.1016/j.ctrv.2014.12.009. Epub 2014 Dec 23.

The emerging role of microRNAs in resistance to lung cancer treatments.

Author information

1
Thoracic Oncology Research Group, School of Clinical Medicine, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St James's Hospital & Trinity College Dublin, Ireland. Electronic address: lmacdona@tcd.ie.
2
Thoracic Oncology Research Group, School of Clinical Medicine, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St James's Hospital & Trinity College Dublin, Ireland. Electronic address: sgray@stjames.ie.
3
Thoracic Oncology Research Group, School of Clinical Medicine, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St James's Hospital & Trinity College Dublin, Ireland; Department of Histopathology, St James's Hospital & Trinity College Dublin, Ireland. Electronic address: Stephen.Finn@tcd.ie.
4
Thoracic Oncology Research Group, School of Clinical Medicine, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St James's Hospital & Trinity College Dublin, Ireland. Electronic address: scuffe@stjames.ie.
5
Thoracic Oncology Research Group, School of Clinical Medicine, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St James's Hospital & Trinity College Dublin, Ireland; Cancer & Ageing Research Program, Queensland University of Technology, Brisbane, Australia. Electronic address: k.obyrne@qut.edu.au.
6
Thoracic Oncology Research Group, School of Clinical Medicine, Institute of Molecular Medicine, Trinity Centre for Health Sciences, St James's Hospital & Trinity College Dublin, Ireland. Electronic address: mbarr@stjames.ie.

Abstract

One of the major challenges in the treatment of lung cancer is the development of drug resistance. This represents a major obstacle in the treatment of patients, limiting the efficacy of both conventional chemotherapy and biological therapies. Deciphering the mechanisms of resistance is critical to further understanding the multifactorial pathways involved, and in developing more specific targeted treatments. To date, numerous studies have reported the potential role of microRNAs (miRNAs) in resistance to various cancer treatments. MicroRNAs are a family of small non-coding RNAs that regulate gene expression by sequence-specific targeting of mRNAs causing translational repression or mRNA degradation. More than 1200 validated human miRNAs have been identified to date. While as little as one miRNA can regulate hundreds of targets, a single target can also be affected by multiple miRNAs. Evidence suggests that dysregulation of specific miRNAs may be involved in the acquisition of resistance to a number of cancer treatments, thereby modulating the sensitivity of cancer cells to such therapies. Therefore, targeting miRNAs may be an attractive strategy for developing novel and more effective individualized therapies, improving drug efficiency, and for predicting patient response to different treatments. In this review, we provide an overview on the role of miRNAs in resistance to current lung cancer therapies and novel biological agents.

KEYWORDS:

Cancer therapies; Chemotherapy; Lung cancer; MicroRNA; Resistance

PMID:
25592062
DOI:
10.1016/j.ctrv.2014.12.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center